Evidence map›Paper›PMID 39470665›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2025

Efficacy of Rezūm water vapor therapy for the treatment of catheter-dependent urinary retention A single-center, Canadian experience.

Ryan Ramjiawan, David Chung, Maximilian G Fidel, Harliv Dhillon, Dhiraj S Bal, Alagarsamy Pandian, Robert Bard, Jasmir G Nayak, Premal Patel

Abstract read
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryan RamjiawanSection of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
David ChungSection of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
Maximilian G FidelMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Harliv DhillonMen's Health Clinic, Winnipeg, MB, Canada.
Dhiraj S BalMax Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Alagarsamy PandianDepartment of Anesthesia, University of Manitoba, Winnipeg, MB, Canada.
Robert BardMen's Health Clinic, Winnipeg, MB, Canada.
Jasmir G NayakSection of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
Premal PatelSection of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionUrinary retention secondary to benign prostatic hyperplasia (BPH) requiring catheterization is a prevalent and morbid condition. The objective of this study was to evaluate the real-world efficacy and safety of Rezūm as the primary treatment of catheter-dependent urinary retention.

methodsA single-center, retrospective study analyzed patients with catheter-dependent urinary retention secondary to BPH who were treated with Rezūm between April 2022 and April 2024. Standardized postoperative followup was required for inclusion. Patient demographics, medication use, volume drained at time of urinary retention, catheter-free status, complications, and postoperative International Prostate Symptom Score (IPSS) was collected.

resultsA total of 53 patients were included. Mean age was 73.4 years (standard deviation 9.4), and the mean Charlson comorbidity index score was 3.7. The baseline mean prostate volume was 81.7 (range 33-179) mL. Patients were catheter-dependent for an average of 225 (range 30-1821) days prior to surgical intervention. Average followup time was 10.2 months. Of the 53 patients treated, 42 (79%) patients were able to become catheter-free after treatment. Twenty-six (49%) patients failed their initial trial of void at 14 days postoperatively; 11% (n=6) of patients experienced hematuria with one admitted to hospital due to hematuria/clot retention. There were no Clavien-Dindo >3 complications. Only retention volume ≥1 L was a significant independent predictor of treatment failure on univariate and multivariate logistic regression analysis.

conclusionsRezūm effectively treated catheter-dependent urinary retention. Given the simplicity of treatment, accessibility, and minimal anesthetic requirements, providers should consider Rezūm to minimize indwelling catheter-related morbidity for catheter-dependant patients.

Identifiers

PMID39470665
PMCPMC11790040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.